Related Experiment Video
Updated: Oct 13, 2026

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
Published on: September 15, 2023
Age-related tumor mutational burden and inflammaging: a pan-cancer multi-omics study of treatment-naïve patients
S Yajima1, Y Tsukada2, Y Sota2
1Department of Urology, National Cancer Center Hospital East, Kashiwa, Japan.
Background:
Aging is a major nonmodifiable risk factor for cancer, yet age-associated genomic instability, inflammatory activation, and tumor microenvironment interactions remain poorly characterized.
Patients And Methods:
The primary genomic cohort comprised 153 treatment-naïve patients with six cancer types, stratified at age 60 years; four additional patients without genomic profiling contributed to nongenomic analyses. Tumor mutational burden (TMB) and fraction genome altered were derived from whole-genome sequencing, and inflammatory pathway activity was determined from single-sample gene set enrichment analysis of RNA sequencing and proteomics in paired tumor and normal tissue. Because cancer type distribution differed between age groups, all principal associations were re-examined in multivariable models.
Results:
TMB was higher in older patients (median 4.55 compared with 2.84 mutations per megabase; P < 0.001) and correlated with age (r s = 0.334, P < 0.001) but was attenuated by adjustment for cancer type and lost significance once microsatellite instability (MSI) status, sex, and stage were added (P = 0.27). Normal-tissue inflammation correlated with paired tumor TMB (protein r s =0.387, P < 0.001) but not after adjustment for age and cancer type (partial r s = 0.07, P = 0.54). MSI-high tumors showed greater tumor-normal inflammation amplification than non-MSI-high tumors (+0.065, P = 0.015), strengthening after adjustment (+0.087, P < 0.001). An immune-hot cluster arose only in older patients but was not independently associated with age (odds ratio 1.03, P = 0.61).
Conclusions:
Most age-associated molecular differences were substantially explained by cancer type. Only the age-related increase in normal-tissue inflammation at the protein level and the greater inflammation amplification of MSI-H tumors persisted. The correlation between normal-tissue inflammation and tumor TMB is not evidence that systemic inflammaging drives genomic instability.
Related Concept Videos
Cancer
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Prevention
Some...